Sanofi scores a snap re­view for a rare dis­ease drug, an­oth­er win for the come­back play­ers in R&D

Just a few months af­ter spot­light­ing promis­ing re­sults from a small study for one of its rare dis­ease drugs, the Sanofi team be­hind an­oth­er one of their rare dis­ease drugs is boast­ing that they snagged a snap re­view at the FDA — the kind that usu­al­ly presages a quick OK.

The drug is su­tim­limab, a C1s in­hibitor which they picked up in their Biover­a­tiv ac­qui­si­tion. The drug is used to treat cold ag­glu­tinin dis­ease, where the im­mune sys­tem runs amok at­tack­ing healthy red blood cells.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER